Author:
Zeng Jiayi,Zhu Ping,Tang Yanlin,Zhang Changzheng,Ye Chujin,Cheng Shouyu,Tian Kaiwen,Yang Bowen,Zeng Weinan,Liu Yanjun,Xian Zhiyong,Yu Yuming
Abstract
AbstractPyroptosis is a kind of programmed cell death triggered by the inflammasome. Growing evidence has revealed the crucial utility of pyroptosis in tumors. However, the potential mechanism of pyroptosis in clear cell renal cell carcinoma (ccRCC) is still unclear. In this research, we systematically analyze the genetic and transcriptional alterations of pyroptosis-related genes (PRGs) in ccRCC, identify pyroptosis-related subtypes, analyze the clinical and microenvironmental differences among different subtypes, develop a corresponding prognostic model to predict the prognosis of patients, and interpret the effect of pyroptosis on ccRCC microenvironment. This study provides a new perspective for a comprehensive understanding of the role of pyroptosis in ccRCC and its impact on the immune microenvironment, and a reliable scoring system was established to predict patients’ prognosis.
Funder
Project of Guangdong Medical Science and Technology Research Foundation
Guangdong Basic and Applied Basic Research Foundation
Foshan Nanhai District “14th Five-Year Plan” key specialty (special specialty) construction project
Project of Department of Finance of Guangdong Province
Publisher
Springer Science and Business Media LLC
Reference64 articles.
1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
2. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
3. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69(1), 7–34 (2019).
4. Chen, V. J. et al. Time on therapy for at least three months correlates with overall survival in metastatic renal cell carcinoma. Cancers (Basel) 11(7), 1 (2019).
5. Bedke, J., Stuhler, V., Stenzl, A. & Brehmer, B. Immunotherapy for kidney cancer: Status quo and the future. Curr. Opin. Urol. 28(1), 8–14 (2018).